


PHARMACEUTICAL 2022

Verastem Inc. Rank 357 of 475







PHARMACEUTICAL 2022

Verastem Inc. Rank 357 of 475



The relative strengths and weaknesses of Verastem Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verastem Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Verastem Inc. is the variable Net Income, reducing the Economic Capital Ratio by 180% points.

The company's Economic Capital Ratio, given in the ranking table, is -297%, being 21% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	105,740
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,590
Liabilities, Non-Current	2,264
Other Assets	2,712
Other Compr. Net Income	-19
Other Expenses	9,972
Other Liabilities	249
Other Net Income	181
Property and Equipment	210
Research and Development	39,347
Revenues	2,053
Selling, General and Administrative Expense	24,115

Output Variable	Value in 1000 USD
Assets	108,662
Liabilities	21,103
Expenses	73,434
Stockholders Equity	87,559
Net Income	-71,200
Comprehensive Net Income	-71,210
Economic Capital Ratio	-297%